John Limanto, Ph.D.

John Limanto, Ph.D., is Senior Director, Process Chemistry, Deerfield Discovery and Development, and joined Deerfield in 2020.  Prior to Deerfield, Dr. Limanto spent more than 18 years with Merck Sharp & Dohme Corp. in the Department of Process Chemistry and held his most recent position as Senior Principal Scientist, Chemistry, since 2016.  Dr. Limanto holds a B.S. in Chemistry from the University of Wisconsin at Madison, an M.S. in Organic Chemistry from Massachusetts Institute of Technology, and a Ph.D. in Organic Chemistry from Boston College.

Hsueh-Cheng (H.C.) Huang, Ph.D.

Hsueh-Cheng (H.C.) Huang, Ph.D., is Senior Director of In Vitro Pharmacology, Deerfield Discovery and Development, and joined Deerfield in 2020. Prior to joining Deerfield, Dr. Huang spent eight years at Merck Research Laboratories, most recently as Principal Scientist/Director in Infectious Diseases and Vaccines, serving as Discovery Biology Lead on discovery, early development, and late-stage product development teams. Before Merck, he worked at Schering-Plough Research Institute, initially as a Postdoctoral Fellow and progressing to the role of Principal Scientist. Dr. Huang holds an A.B. in Physics and a Ph.D. in Cell & Developmental Biology from Harvard University.

Schuyler Kennedy

Schuyler Kennedy is Executive Assistant, Deerfield Discovery and Development, and joined Deerfield in 2020. Prior to Deerfield, Ms. Kennedy spent two years as a Care Coordinator in the pediatric, outpatient chemotherapy unit for Memorial Sloan Kettering Kids.  She holds a B.S. in Psychology from Fordham University and completed premedical requirements at Columbia University’s post-baccalaureate program.

Mollie Ranalletta, Ph.D.

Mollie Ranalletta, Ph.D., is Senior Director, Project Management, Deerfield Discovery and Development, and joined Deerfield in 2020. Prior to Deerfield, Dr. Ranalletta worked at the Merck Research Laboratories for almost 14 years – first as a Senior Research Biologist and then as part of the Global Project and Alliance Management team in roles of increasing responsibility. Dr. Ranalletta holds a B.S. and M.S. in Animal Sciences from Purdue University. She earned her Ph.D. in Biochemistry at the Albert Einstein College of Medicine, Yeshiva University, and finished her training as a Postdoctoral Research Fellow at Columbia University Medical Center. 

Gilead Kedem, M.D.

Gilead Kedem, M.D., is Director, Bioinformatics, Deerfield Discovery and Development, and joined Deerfield in 2020. Prior to Deerfield, Dr. Kedem spent almost 20 years in biotech, focusing on software development, bioinformatics, genomics, and precision medicine. Most recently, Dr. Kedem consulted for Regeneron Pharmaceuticals and beforehand was Manager, Bioinformatics at GENEWIZ, a global sequencing company. Earlier, Dr. Kedem served as Chief Technology Officer and Chief Medical Officer of a metagenomics-based diagnostics startup. Previously, Mr. Kedem founded a boutique consultancy, Kedem Associates, in Cambridge, Massachusetts, and ran it for over a decade. Kedem Associates developed advanced bioinformatics systems and provided strategic advice for clients engaged in drug discovery, diagnostics, and precision medicine. Dr. Kedem holds a B.S. in Physics from the University of Maryland at College Park, pursued graduate studies in biomedical engineering at Johns Hopkins University, and earned an M.D. from the Sackler School of Medicine at Tel Aviv University, Israel.

Coco Dong, Ph.D.

Coco Dong, Ph.D., is Senior Genetic Data Scientist, Deerfield Discovery and Development, and joined Deerfield in 2020. Prior to Deerfield, Dr. Dong was a Strategist in the Alternative Investment and Manager Selection group at Goldman Sachs. Before Goldman Sachs, she was a Principal Statistician at GlaxoSmithKline. Dr. Dong holds a B.S. in Biomedical Science from Central South University in China, as well as a M.S. in Computer Science and a Ph.D. in Biostatistics from the University of Southern California.

Andrew Stamford, Ph.D.

Andrew (Andy) Stamford, Ph.D., is Vice President, Chemistry, Deerfield Discovery and Development, and joined Deerfield in 2020. Prior to Deerfield, Dr. Stamford spent more than three years at Bridge Medicines as Vice President, Chemistry, and then as Senior Vice President of Research and Development. During this time, he also served as Vice President, Chemistry at the Tri-Institutional Therapeutics Discovery Institute. Dr. Stamford has over 25 years of combined experience at Merck and Schering-Plough Research Institute working in small molecule drug discovery from hit-to-lead to clinical candidate. He is the co-author of more than 70 peer-reviewed publications and an inventor on over 100 issued U.S. patents. Dr. Stamford holds a B.Sc. in Organic Chemistry from University of Tasmania and a Ph.D. in Organic Chemistry from University of Sydney.

Anthony Barsotti, Ph.D.

Anthony Barsotti, Ph.D., is Director, In Vitro Pharmacology, Deerfield Discovery and Development, and joined Deerfield in 2020.  Prior to Deerfield, Dr. Barsotti served as Director of Target Discovery Biology at Inzen Therapeutics. Before Inzen, he served as a Principal Scientist (Molecular Signaling) at Kadmon Corporation. He began his career as a Post-Doctoral Fellow at Pfizer in the Oncology Research Unit. Dr. Barsotti holds a B.A. in Biochemistry from the University of Pennsylvania and a Ph.D. in Biological Sciences from Columbia University.

Julianne Hunt, Ph.D.

Julianne Hunt, Ph.D., is Executive Director, Project Management, Deerfield Discovery and Development, and joined Deerfield in 2019. Prior to Deerfield, Dr. Hunt was Vice President, Scientific Operations, at Abide Therapeutics. Before Abide, she worked at Merck Research Laboratories for more than 16 years in various research and operational roles, including Director, Strategic Alliances, and Director, Strategic Operations. Dr. Hunt holds an A.B. in Chemistry from Harvard University and a Ph.D. in Organic Chemistry from Indiana University, and she was an NIH Postdoctoral Fellow at Princeton University.

Matthew Nelson, Ph.D.

Matthew Nelson, Ph.D., is Vice President, Genetics and Genomics, Deerfield Discovery and Development, and joined Deerfield in 2019. Prior to Deerfield, Dr. Nelson spent almost 15 years at GlaxoSmithKline and was most recently the Head of Genetics. Prior to GlaxoSmithKline, Dr. Nelson was the Director of Biostatistics at Sequenom. He began his career as an information scientist at Esperion Therapeutics. Dr. Nelson was an Adjunct Associate Professor of Biostatistics at the University of North Carolina from 2010 to 2016. He holds a Ph.D. in Human Genetics and an M.A. in Statistics from the University of Michigan and obtained his B.S. in Molecular Biology from Brigham Young University.